Jaiswal Bijay S, Janakiraman Vasantharajan, Kljavin Noelyn M, Chaudhuri Subhra, Stern Howard M, Wang Weiru, Kan Zhengyan, Dbouk Hashem A, Peters Brock A, Waring Paul, Dela Vega Trisha, Kenski Denise M, Bowman Krista K, Lorenzo Maria, Li Hong, Wu Jiansheng, Modrusan Zora, Stinson Jeremy, Eby Michael, Yue Peng, Kaminker Josh S, de Sauvage Frederic J, Backer Jonathan M, Seshagiri Somasekar
Department of Molecular Biology, Genentech Inc., South San Francisco, CA 94080, USA.
Cancer Cell. 2009 Dec 8;16(6):463-74. doi: 10.1016/j.ccr.2009.10.016.
Members of the mammalian phosphoinositide-3-OH kinase (PI3K) family of proteins are critical regulators of various cellular process including cell survival, growth, proliferation, and motility. Oncogenic activating mutations in the p110alpha catalytic subunit of the heterodimeric p110/p85 PI3K enzyme are frequent in human cancers. Here we show the presence of frequent mutations in p85alpha in colon cancer, a majority of which occurs in the inter-Src homology-2 (iSH2) domain. These mutations uncouple and retain p85alpha's p110-stabilizing activity, while abrogating its p110-inhibitory activity. The p85alpha mutants promote cell survival, AKT activation, anchorage-independent cell growth, and oncogenesis in a p110-dependent manner.
哺乳动物磷酸肌醇-3-羟基激酶(PI3K)蛋白家族成员是多种细胞过程的关键调节因子,包括细胞存活、生长、增殖和运动。异二聚体p110/p85 PI3K酶的p110α催化亚基中的致癌激活突变在人类癌症中很常见。在这里,我们展示了结肠癌中p85α存在频繁突变,其中大多数发生在Src同源结构域2(iSH2)之间。这些突变使p85α的p110稳定活性解偶联并保留,同时消除其p110抑制活性。p85α突变体以p110依赖的方式促进细胞存活、AKT激活、不依赖贴壁的细胞生长和肿瘤发生。